middle.news
How Will Arovella’s FDA Nod for ALA-101 Shape Its Clinical Future?
3:12pm on Thursday 19th of February, 2026 AEDT
•
Biotechnology
Read Story
How Will Arovella’s FDA Nod for ALA-101 Shape Its Clinical Future?
3:12pm on Thursday 19th of February, 2026 AEDT
Key Points
Half-year loss increased 22% to $1.88 million
Revenue steady at $3.62 million, driven by R&D tax incentives
FDA accepted IND application for ALA-101 post-period
Progress in CAR-iNKT platform targeting solid tumours with promising preclinical data
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Arovella Therapeutics (ASX:ALA)
OPEN ARTICLE